Health Canada Actively Reviewing Submissions From Pfizer-Biontech Seeking Authorization Of Covid-19 Vaccine Targeting Omicron XBB.1.5 Subvariant
Portfolio Pulse from Benzinga Newsdesk
Health Canada is actively reviewing submissions from Pfizer-BioNTech for the authorization of their COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant, according to Reuters.
September 12, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's stock could be impacted by Health Canada's review of their COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant.
The review by Health Canada of Pfizer's COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant could potentially lead to increased sales and revenue for the company if approved. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100